Meeting
2017 ASCO Annual Meeting
Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.
Authors
Todd S. Crocenzi
Providence Cancer Center, Portland, OR
Todd S. Crocenzi , Anthony B. El-Khoueiry , Thomas Cheung Yau , Ignacio Melero , Bruno Sangro , Masatoshi Kudo , Chiun Hsu , Jorg Trojan , Tae-You Kim , Su-Pin Choo , Tim Meyer , Yoon-Koo Kang , Winnie Yeo , Akhil Chopra , Adyb Baakili , Christine Marie Dela Cruz , Lixin Lang , Jaclyn Neely , Theodore Welling
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT01658878
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4013)
DOI
10.1200/JCO.2017.35.15_suppl.4013
Abstract #
4013
Poster Bd #
5
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.
First Author: Ignacio Melero
Poster
2020 Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.
First Author: Aiwu Ruth He
Poster
2019 Gastrointestinal Cancers Symposium
Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.
First Author: Masatoshi Kudo
Poster
2019 ASCO Annual Meeting
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
First Author: Thomas Yau